Profiling the Impact of mGlu 7 /Elfn1 Protein Interactions on the Pharmacology of mGlu 7 Allosteric Modulators
ACS Chemical Neuroscience · 2025
DOI: 10.1021/acschemneuro.5c00174 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2025. Verfasst von Xia Lei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, U…. Hauptthemen laut MEDLINE: Receptors, Metabotropic Glutamate, Nerve Tissue Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMH NIH HHS, NINDS NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
The group III metabotropic glutamate receptors (mGlu receptors) are predominantly expressed presynaptically throughout the central nervous system (CNS) where they regulate the release of glutamate and GABA. These receptors have recently been shown to be anchored by transsynaptic expression of the laminin proteins ELFN1 and ELFN2. In particular, the mGlu7 receptor is localized at presynaptic active zones from pyramidal cells to somatostatin-containing interneurons with postsynaptic ELFN1, and this interaction drives the rapidly facilitating nature of these synapses in the hippocampus and cortex. Interestingly, individuals with mutations in ELFN1 or GRM7 genes present with attention-deficit hyperactivity disorder and epilepsy, and knockout mice of each of these proteins develop seizures with very similar time courses. In the current manuscript, we explore the hypothesis that the pharmacology of positive and negative allosteric modulators (PAMs and NAMs) of mGlu7 might be changed in the presence of ELFN1. These results showed that, across a range of NAMs, we observed similar efficacy in the presence of ELFN1. For PAMs, we observed decreased maximal potentiation when ELFN1 was present, but all examined compounds were still able to potentiate receptor signaling regardless of ELFN1 expression. Finally, we confirm that a tool PAM with mGlu7 activity is able to potentiate responses at pyramidal cell-somatostatin interneuron synapses where ELFN1 is expressed. These results suggest that, for the modulators shown here, native tissue activity should be retained in the presence of ELFN1 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
- Vanderbilt Institute of Chemical Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
- Vanderbilt Brain Institute, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
- Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
ORCID-Profile: Zixiu Xiang, Alice L Rodriguez, Colleen M Niswender
Förderung
- NIMH NIH HHS
- NINDS NIH HHS
- NICHD NIH HHS
- William K. Warren Foundation
- National Institutes of Health
Zitieren
APA
Lei, X., Xiang, Z., Rodriguez, A. L., Wilson, M. L., & Niswender, C. M. (2025). Profiling the Impact of mGlu 7 /Elfn1 Protein Interactions on the Pharmacology of mGlu 7 Allosteric Modulators. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.5c00174
Vancouver
Lei X, Xiang Z, Rodriguez AL, Wilson ML, Niswender CM. Profiling the Impact of mGlu 7 /Elfn1 Protein Interactions on the Pharmacology of mGlu 7 Allosteric Modulators. ACS Chemical Neuroscience. 2025. doi:10.1021/acschemneuro.5c00174
BibTeX
@article{Lei2025,
author = {Lei, Xia and Xiang, Zixiu and Rodriguez, Alice L and Wilson, Margaret L and Niswender, Colleen M},
title = {Profiling the Impact of mGlu 7 /Elfn1 Protein Interactions on the Pharmacology of mGlu 7 Allosteric Modulators},
journal = {ACS Chemical Neuroscience},
year = {2025},
doi = {10.1021/acschemneuro.5c00174}
}
EUVIMED